Cell cycle phase dependence of estrogen and epidermal growth factor (EGF) receptor expression in MCF-7 cells: implications in antiestrogen and EGF cell responsiveness.

In this report the effect of epidermal growth factor (EGF) and the antiestrogen hydroxytamoxifen (OH-TAM) on the cell cycle of the breast cancer cell line MCF-7 was investigated as a function of the presence of their respective receptors. For this study synchronized cells were obtained by cell incubation in the presence of 2 mM thymidine for 24 h at 37 C. The treatment led to a partial synchronization, since at the end of thymidine treatment, 80% of cells were accumulated in the G1 phase. The removal of thymidine allowed the cells to progress through the cell cycle, since between 6-9 h after the arrest of the treatment, about 50% of cells were found in the S phase. By 9-12 h, most of the cells entered the G2 phase, and by 24 h, the cells returned to the G1 phase. When MCF-7 cells were incubated in the presence of OH-TAM for various periods of time before thymidine exposure, the progression of the cells through the cell cycle was dramatically inhibited. Also, a short term antiestrogen treatment (2 h) before or immediately after the addition of thymidine led to an accumulation of MCF-7 cells in the G1 phase. However, when the cells were treated for 2 h with OH-TAM 22 h after thymidine addition or shortly after its removal from the cell culture, no effect of the antiestrogen on the cell cycle could be observed. In parallel, the effect of thymidine on the level of estrogen receptor was studied. Although low affinity estrogen-binding sites were maintained, high affinity ER were found to be dramatically reduced during the thymidine treatment. The comparison between the effect of OH-TAM on the cell cycle and the expression of ER revealed that the antiestrogen OH-TAM was effective only in the presence of ER. EGF was found to have no effect on the cell cycle of thymidine-synchronized cells, although it did partially reverse the G1 phase block induced by OH-TAM when added simultaneously to cell culture 24 h before thymidine exposure. The parallel analysis of EGF receptor level demonstrated that thymidine treatment also reduced EGF receptors that were found to reappear after the synchronization, during the S and G2 phases of the cell cycle.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  V. Schirrmacher,et al.  Cellular distribution and biological activity of epidermal growth factor receptors in A431 cells are influenced by cell‐cell contact , 1990, Journal of cellular physiology.

[2]  N. Brünner,et al.  Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. , 1989, Cancer research.

[3]  X. F. Dong,et al.  Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. , 1989, Biochemical and biophysical research communications.

[4]  Y. Berthois,et al.  Growth factors and oncogenes. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  R. Sutherland,et al.  Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and insulin. , 1989, Cancer research.

[6]  A. Wakeling,et al.  Biology and mode of action of pure antioestrogens. , 1989, Drugs under experimental and clinical research.

[7]  P. Chambon,et al.  The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer , 1988, Cell.

[8]  P. Chambon,et al.  The human oestrogen receptor functions in yeast , 1988, Nature.

[9]  J. Eisman,et al.  Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells. , 1988, Cancer research.

[10]  L. Andrac,et al.  Multiparametric study (SAMBA 200) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas: analysis of estrogen receptor distribution heterogeneity in tissues and correlations with dextran coated charcoal assays and morphological data. , 1988, Cancer research.

[11]  J. Pasqualini,et al.  Control of progesterone receptors in fetal uterine cells in culture: effects of estradiol, progestins, antiestrogens, and growth factors. , 1988, Endocrinology.

[12]  H. Rochefort,et al.  Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. , 1987, Biochemical and biophysical research communications.

[13]  Gerhart U. Ryffel,et al.  An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells , 1986, Cell.

[14]  U. Eppenberger,et al.  Effects of Hormones and Growth Factors on the Growth of Six Human Breast Cancer Cell Lines in Defined Media1 , 1986 .

[15]  R. Dickson,et al.  Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. , 1986, Science.

[16]  B. Katzenellenbogen,et al.  Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Murphy,et al.  Progestin regulation of epidermal growth factor receptor in human mammary carcinoma cells. , 1986, Cancer research.

[18]  R. Dickson,et al.  Role of estrogens in the malignant progression of breast cancer: new perspectives , 1986 .

[19]  R. Dickson,et al.  Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. , 1986, Endocrinology.

[20]  I. Christensen,et al.  Cell cycle analysis of estrogen stimulation and antiestrogen inhibition of growth of the human breast cancer cell line MCF-7. , 1986, Breast cancer research and treatment.

[21]  M. Fernö,et al.  Antiestrogen binding sites in human breast cancer biopsies. Measurement ligand-specificity and affinity, and correlation to estrogen and progesterone receptors. , 1985, Anticancer research.

[22]  Anita B. Roberts,et al.  Autocrine growth factors and cancer , 1985, Nature.

[23]  G. Schultz,et al.  Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. , 1984, Cancer research.

[24]  I. Christensen,et al.  Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7. , 1984, British Journal of Cancer.

[25]  C. Osborne,et al.  Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. , 1984, Cancer research.

[26]  J. Wittliff.  Steroid‐hormone receptors in breast cancer , 1984, Cancer.

[27]  B. Katzenellenbogen,et al.  Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. , 1984, Endocrinology.

[28]  W. Schuette,et al.  Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells. , 1984, Cancer research.

[29]  G. Greene,et al.  Immunochemical studies of estrogen receptors. , 1984, Journal of steroid biochemistry.

[30]  B. Katzenellenbogen,et al.  Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. , 1983, Cancer research.

[31]  O. Kon.  An antiestrogen-binding protein in human tissues. , 1983, The Journal of biological chemistry.

[32]  R. Sutherland,et al.  Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. , 1983, European journal of cancer & clinical oncology.

[33]  L. Murphy,et al.  High-affinity anti-oestrogen binding site distinct from the oestrogen receptor , 1980, Nature.

[34]  C. Osborne,et al.  Epidermal growth factor stimulation of human breast cancer cells in culture. , 1980, Cancer research.

[35]  M. Lippman,et al.  Oestrogen-responsive human breast cancer in long term tissue culture , 1975, Nature.

[36]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.